Introduction
Schizophrenia (Sz) is a devastating psychiatric disorder that is considered to be one of the most incapacitating mental illnesses in modern medicine. This disorder generates a considerable global economic burden on national healthcare budgets due to the annual financial costs required to treat it (1) . It affects approximately 1% of the worldwide population (2) . In a clinical sense, Sz is characterized by positive symptoms (e.g., delusions, hallucinations), negative symptoms (e.g., anhedonia, avolition, social withdrawal, lack of personal hygiene), and cognitive impairments (e.g., working memory problems and poor attention) (3, 4) .
Although this disorder is caused by both the individual's genes and the environment, the biological background of this illness has been misleading (5) . Sz has a complex genetic architecture with multiple genes that contribute to the etiology and the risk of this disease. Moreover, regardless of the huge amount of research made in the field, the molecular etiology of Sz is still in its early stages (6, 7) . Some of the proposed candidate genes of Sz are DRD2, DRD3, , COMT, SLC1A6, SLC1A2,  GRIN1, GRIN2A, GRIA1, NRG1, ERBB4, DTNBP1,  DAAO, G72/30, GRM3, DISC1, RGS4, PRODH, DGCR6,  ZDHHC8, DGCR2, CREB, IL-1B, IL-1RN, IL-10, IL-1B,  TRAR4 , PPP3CC, and AKT1 (8, 9) .
The ERBB4 gene is located on human chromosome 2 (2q34) (10) . It is one of four members of the erbB receptor tyrosine kinase (RTK) family. The main functions of this family are cell growth regulation, cell survival, maturation and apoptosis of the neurons, cell proliferation, and cell differentiation. The erbB family contains four genes: erbB1, erbB2, erbB3, and ERBB4 (11, 12) . In terms of size, ERBB4 is a large gene consisting of approximately 1.16 Mb that includes 28 exons encoding for type 1 transmembrane tyrosine kinase (10, 13) . There are four isoforms of ERBB4 that have been characterized due to alternative splicing of the ERBB4 transcript (12) . Structurally, the ERBB4 receptor is composed of the following components: an extracellular ligand binding domain, an intracellular juxtamembrane (JM) region, a single transmembrane domain, a tyrosine kinase domain, and a carboxyterminal tail (14) . The ERBB4 gene is found to be expressed in the human heart, kidneys, neuronal tissues, renal tissues, and breasts and in most areas of the adult brain (15) .
The role of ERBB4 in the pathophysiology of Sz is evident at the biological level for many reasons (10, 16, 17) . First, expression of ERBB4 is detected in the developing and adult human brain neurons. Second, the NRG1-ERBB4 signaling pathway is involved in neurobiological operations comprising neurogenesis, synapsis formation and plasticity, neuronal migration, and axon guidance, all of which are hypothesized to be disturbed in Sz. The NRG1 protein acts as a ligand for the erbb4 receptor to form the NRG1-ERBB4 complex. After the binding, the ligandreceptor complex prompts dimerization and activates the tyrosine kinase receptor, resulting in phosphorylation of the receptor's cytoplasmic domain. Sequentially, this generates a docking site for adaptor proteins like Shc, Grb2, and the regulatory subunit of phosphoinositide-3-kinase (PI3-kinase), which in turn results in the activation of downstream signaling pathways such as the Ras-Raf-MAPK and the PI-3 kinase pathways that are involved in the mediation of various biological functions. For instance, in neurodevelopment, these pathways participate in neuronal migration, glial cell development, axon myelination and guidance, dendritic development, and neurotransmitter signaling (10, (16) (17) (18) . Third, mutant mice heterozygous for ERBB4 show a Sz-related behavioral phenotype. Furthermore, the brains of schizophrenic patients are reported to have changes in NRG1-mediated ERBB4 activation as well as changes in the gene expression of the ERBB4 splice isoform (12) .
Few genetic association studies have been conducted to reveal the role of ERBB4 in Sz (10). However, Norton et al. reported that variants in ERBB4 were associated with an increased risk of Sz (11) . Two other studies conducted by Silberberg et al. and Law et al. independently replicated the findings of Norton et al., and they found that three intronic single nucleotide polymorphisms (SNPs), rs7598440, rs839523, and rs707284, are associated with the risk of Sz (12, 19) . Nicodemus et al. stated that a haplotype containing rs3748962-G has an association with Sz. Furthermore, the ratio of A/G of allelic expression of ERBB4 mRNA at this SNP was detected in a study conducted by Norton et al. (11) on brain mRNA expression in maternal and paternal chromosomes. This result further explained that the possibility of another cis-acting polymorphism also affects the expression of ERBB4. Therefore, either rs3745962 or another functional polymorphism in LD with rs3745962 could be associated with Sz. Unfortunately, the effect of rs3745962 on ERBB4 function has not been clarified yet.
In this study, we describe the allelic and genotypic distribution of SNPs in the ERBB4 gene in Jordanian patients of Arab descent diagnosed with Sz, and we investigate the association between the ERBB4 gene polymorphisms and Sz among Jordanian patients of Arab descent. 
Materials and methods

Study samples
DNA genotyping
Genomic DNA was extracted within 1 week of blood collection via the commercially available Puregene Blood Core Kit B (QIAGEN, Germany) according to the manufacturer's instructions. Yield (ng/µL) and purity (A260/280) of the extracted DNA were measured using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technology, USA). DNA was amplified using specific primers that map to the ERBB4 gene, and the primers were designed using Primer 3 Software (http://primer3. ut.ee/). Table 1 summarizes the primer sequences and the predicted product sizes of the polymerase chain reaction (PCR)-amplified products for the ERBB4 gene.
The PCR reaction was optimized for the amplification protocol and an optimal annealing temperature of 60 °C was used (Applied Biosystems, USA). The amplification . Next, 5 µL of each PCR product and 5 µL of 100-bp ladders (Thermo Scientific, USA) were loaded into wells of 2% agarose gel and 3 µL of 10 mg/mL ethidium bromide (Bio Basic Inc., Canada) was added to the gel to stain the DNA band for visualization. The gel was run using 1X Tris-borate-EDTA (TBE) running buffer (prepared from 10X TBE: 108 g of Tris, 55 g of boric acid, and 40 mL of 0.5 M EDTA dissolved in up to 2 L distilled water) using an electrical current source of 150 V for 35 min. Gel documentation was done under a UV transilluminator supplied with a gel documentation system (Bio-Rad, USA). The PCR product size was measured by matching with known band sizes of the ladder. The PCR product was purified to remove the unwanted PCR component by using the EZ-10 Spin Column PCR Products Purification Kit (Bio Basic Inc.) according to the manufacturer's instructions. After purification of the PCR product, samples were ready for the sequencing reaction protocol. Briefly, 1 µL of Ready Reaction Mix was mixed with 4 µL of sequencing buffer, 5 µL of nuclease-free water, 2 µL of forward primer (singlesided sequencing reaction), and 2-3 µL of purified DNA in a PCR tube and vortexed. The sample was loaded on a thermocycler (Applied Biosystems) according to the following protocol: stage 1 (25 cycles), denaturation (96 °C for 10 s), annealing (50 °C for 5 s), and extension (60 °C for 4 min); and stage 2 (1 cycle), 4 °C for infinity. The PCR sequencing products were cleaned to remove small molecules from the nucleic acids. This cleaning was performed according to the manufacturer's instructions with a special cleaning kit (NucleoSEQ, Germany). The sample was then either directly loaded on the genetic analyzer (3130x1, Applied Biosystems) using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) or stored at -20 °C.
Chromatogram analysis
DNA sequence chromatograms were visualized using Chromas Pro software v.1 (USA). The chromatograms were also compared to a reference sequence (Ensembl ID: ENSG00000178568) that was obtained from the Ensembl genome browser (http://www.ensembl.org/index. html) to search for abnormalities, deletions, insertions, substitutions, or heterozygosity.
Statistical analysis
A sequencing technique was used to genotype the two SNPs (rs839523 and rs3748962) within the ERBB4 gene. In order to determine if the population fulfilled the HardyWeinberg equilibrium (HWE) equation (p² + 2pq + q² = 1), the genotyping frequency was calculated using the HWE calculator (20) involving analysis for ascertainment bias. SPSS 19.0 was used in statistical analysis. The chisquare test was used to determine the P-value of the allele and genotype association between Sz patients and healthy control individuals. Variations in allele and genotype frequencies between patients and controls were assessed using case-control genetic association analysis. P < 0.05 was considered to be statistically significant.
Results
Sample characteristics
All 185 patients were diagnosed with Sz and met the criteria set by the DSM-IV. Patients were excluded if they displayed one of the following symptoms: diagnosis of bipolar disorder, schizoaffective disorder, major depression, and/or mental retardation. Patients with serious health and medical conditions were also excluded. Sample collection from patients was difficult due to the social stigma against mental health. Therefore, many families and patients refused to give blood samples or clinical information. A total of 195 control DNA samples were collected from unrelated matched healthy Jordanian individuals. Controls were excluded if they had a history of drug dependence, alcohol dependence, mental health problems, and/or psychosis. Detailed information on Sz patients and healthy individuals is summarized in Table  2 . Clinical data were collected from the patient's medical records, as summarized in Table 3 . 
Polymerase chain reaction and gel electrophoresis
Two SNPs were selected for genotyping and amplified within the ERBB4 genomic sequence, located in intron 2 (rs839523) and exon 27 (rs3748962) as shown in Figure 1 . PCR analysis was conducted to show if the amplified fragments for each SNP had the expected sizes in all patients and controls and to verify the absence of contamination in PCR products. If no bands were visualized for any DNA sample on the gel, the DNA sample was reamplified again using different concentrations of either the primers or DNA.
Samples from 185 patients and 198 healthy individuals were amplified and sequenced successfully. All the fragments were loaded on 2% agarose gel and the size of each fragment was determined against a 100-bp ladder. The size of the amplified fragment product for rs839523 was 401 bp and 513 bp as shown in Figures 2 and 3 , respectively.
DNA sequencing and genotyping analysis
After the PCR amplified products were purified, the purified DNA fragments were amplified again using sequencing PCR by forward primer. All the amplified fragments for the two SNPs (rs3748962, intron 1 and rs839523, exon 27) in the ERBB4 gene were sequenced and the electropherogram sequences were blasted against their reference sequences (www.ensemble.org), and then the changes in bases of the SNPs were identified and tabulated in Excel sheet format.
The rs839523 SNP is located in intron 2 of the gene and changes G to A (Figure 4) . Eighty-six patients were found to have the homozygous ancestral allele of GG, 74 patients had the heterozygous allele of GA, and 25 patients had the homozygous allele of AA for this polymorphism. The rs3748962 SNP is located in exon 27 of the gene and changes A to G ( Figure 5 ). One hundred and six patients were found to have the homozygous ancestral allele of AA, 61 patients had the heterozygous allele of AG, and 18 patients had the homozygous allele of GG for this polymorphism.
Allelic and genotypic distribution of schizophrenia patients and healthy individuals
The distribution of the rs839523 and rs3748962 genotypes between the Sz patients and controls was assessed. The genotyping frequency of the rs839523 SNP was different between patients and controls. The GG genotype frequency was 46.5% in patients while it was 30.8% in controls. Furthermore, the G allele frequency was 66.5% and 55.8% in patients and controls, respectively. In contrast, the AA genotype and A allele frequencies were at 13.5% and 33.5% in patients, respectively, while in controls they were at 19.2% and 44.2% for the AA genotype and A allele frequencies, respectively. The heterozygous genotype showed a 40% frequency compared to 50% frequency in controls.
However, no major differences in genotypic and allelic frequencies of the rs3748962 SNP were detected between schizophrenic patients and controls. The AA genotype frequency was 57.3% in patients but it was 49.5% in controls. Furthermore, the heterozygous genotype frequency was 33% in patients while it was 44.4% in controls. The GG frequency was found to be 9.7% in cases compared to 6.1% in controls. The A allele frequencies were 73.8% and 71.7% in patients and controls, respectively. In addition, the G allele frequencies were 26.2% in schizophrenic patients and 28.3% in controls. Genotype and allele frequencies were evaluated for concordance with HWE. The rs839523 SNP in cases and controls were in HWE, but the rs3748962 SNP in cases was slightly out of HWE at P = 0.0446 (Table 4) .
Genetic association of rs839523 and rs374896) SNPs with schizophrenia using different genetic models
The genotype and allele frequencies of the rs839523 SNP in the Sz cases differed significantly from those of the controls (P = 0.006 for genotype and P = 0.002 for allele). No significant differences were observed in the rs3748962 genotype and allele frequencies between Sz cases and controls (P = 0.05 for genotype and P = 0.52 for allele) ( Table 5) .
Genetic association analysis of the two SNPs genotyped in the Sz cases and controls was also conducted using dominant, additive, and recessive genetic models (Table  5 ). For rs839523, the heterozygous GA versus common homozygous GG and rare homozygous AA versus common homozygous GG categories were statistically significant (chi-square > 3.84, P < 0.05). In contrast, rare homozygous AA versus heterozygous GA showed no statistical significance. In contrast, for the other SNP, rs3748962, rare homozygous GG versus heterozygous AG and rare homozygous GG versus common homozygous AA were found to be statistically insignificant (P > 0.05). However, heterozygous AG versus common homozygous AA was significant (Table 5 ).
Discussion
Complex genetic diseases such as hypertension, diabetes, cancer, coronary heart diseases, and most psychiatric disorders (e.g., schizophrenia) follow a non-Mendelian mode of inheritance (21) . The complexity in genetic architecture confers a critical burden in Sz research (22) . However, genetic and functional analyses provide evidence of the association between the ERBB4 gene and Sz. Therefore, various genetic epidemiology studies have proposed ERBB4 as a candidate susceptibility gene for Sz. ERBB4 is one of the ErbB family receptor genes, which has the most recognized functions in the central nervous system among these subfamilies (23) . Because of the previous association of ERBB4 with Sz in the literature, this study focused on the association of two SNPs of the ERBB4 gene with Sz in a Jordanian population of Arab descent. To the best of our knowledge, this study is the first in the field of psychiatric genetics research in Jordan and in people of Arab descent in general.
Only male patients were recruited in this study for many reasons. Culture is the main factor responsible for the bias. For example, the stigma of mental health contributes to negative attitudes towards giving blood samples and medical information. Most of the interviewed females patients refused to give blood because of fear or distrust. The currently used diagnostic criterion in Jordan is the DSM-IV. This criterion is used in most of the psychiatric hospitals in the country, which is the reason why the DSM-IV was used in this research.
In this study, a genetic association was found between the rs839523 genotype and male Sz patients (P = 0.006). In contrast, the rs3748962 genotype showed no statistically significant association with the disease (P = 0.05). Analyses of genetic association using different genetic models (dominant, additive, and recessive) were conducted to confirm the association of the variant's genotypes between Sz cases and controls. The results of the genetic models also P < 0.05 is significant for allelic and genotypic associations (in bold). *For significant association, the chi-square value should be >3.84 with P < 0.025 for the genetic association model test (in bold). CI: confidence interval. confirm the association between the rs839523 SNP and Sz. The association was found in the heterozygous AG versus common homozygous GG model and in rare homozygous AA versus common homozygous GG (chi-square > 3.84 and P < 0.05 for both models). On the other hand, none of the genetic models showed a significant association with the rs3748962 SNP. Despite the convincing evidence of the involvement of ERBB4 in the progression of Sz, comparatively few genetic association studies have been performed in different populations, including Ashkenazi Jews, Americans (Caucasians and African-Americans), and Han Chinese (19, 24, 25) . Comparing the genotypic frequency results in this study with other populations provides an insight into the differences between populations and ethnic groups in terms of disease risk. This comparison of the rs839523 polymorphism results of this study with other populations (Table 6 ) revealed an inconsistency in frequencies of each genotype. For example, Silberberg et al. reported the first genetic association study between different ERBB4 SNPs and Sz in Ashkenazi Jews. They found a highly significant genotypic and allelic association of the rs839523 SNP (P = 0.000021 and P = 0.0045, respectively) and Sz disorder (19) . In their study, the GG genotype frequency was 55.9% in Sz cases and it was only 23.8% in controls, while in our study the GG genotype showed a frequency of 46.5% in Sz cases and 30.8% in controls. In Asian populations, a relatively similar frequency result is found between different genetic association studies. For example, the GG genotype frequency in Sz cases was 38% in China (13), 30.8% in Taiwan (25) , and 35.7% in Japan (26) , and those studies reported no association between this SNP and Sz. Our results are consistent with the results shown in Ashkenazi Jews (19) , but they are not consistent with the results reported in Korean (10), Han Chinese in China (13), Taiwanese (25) , and Japanese (26) populations.
In the case of rs3748962 (Val1065Val), our result is consistent with the results found in the UK population (P = 0.94885) and in Ashkenazi Jews (16, 19) , but not consistent with those shown in Taiwanese (P = 0.0027 for genotype and P = 0.0007 for allele) or Korean populations (10, 25) . The discrepancy between results is due to the differences between ethnicities and the population stratification in the different studied populations. The variations in genotype and allele frequencies between several studies are also related to the lack of replication in different populations. However, the risk of population stratification in this study is unlikely because the Jordanian population is considered to be a genetically homogeneous population. Jordanians are descended from villagers and a Bedouin lineage originating in the Arabian Peninsula (27) . Notably, the majority of the population is Arab (nearly 98%), and the remaining 2% is divided equally into Armenians and Circassians. Minor ethnic factions include the Kurds, Druze, and Chechens (28) .
The possible explanation of the association of rs839523 with the risk of Sz might be related to a change of expression of the CYT-1 isoform in the brain. Silberberg et al. reported that three SNPs (rs707284, rs839523, rs7598440) in ERBB4 exhibited highly significant differences between Sz cases and controls. They also were from one linkage disequilibrium block with significant P-values for allele frequencies (P = 0.013, 0.0045, and 0.0049, respectively), genotype frequencies (P = 0.00013, 0.000021, and 0.00018, respectively), and risk haplotype frequency (P = 0.00044). This haplotype is tightly linked to the overexpression of a splice variant encompassing exon 26 (CYT-1). CYT-1 is found to be overexpressed in the postmortem dorsolateral prefrontal cortex of Sz cases (P = 0.047). The CYT-1 domain acts as a phosphoinositide 3-kinase (PI3-K) binding site and leads to the activation of the PI3-K/Akt pathway. Akt1 might contribute to the pathophysiology of Sz as several studies reported a positive association with the disorder (19) .
Law et al. replicated the study of Silberberg et al. and found an association between these three SNPs and an elevated level of expression of the CYT-1 isoform in the patient's brain (12) . Another study using a large sample of Sz families and controls found an association of the rs7598440, rs839541, and rs839523 SNPs surrounding exon 3 of ERBB4 with Sz, and this finding was confirmed in African-American families (24) .
The divergence in the results between different published studies might be due to population stratification and ethnic differences. For example, the rs3748962 SNP in cases was found to deviate slightly from HWE. This deviation could be a result of population homogeneity, since Jordan is considered as an isolated population. It is also possible that the presence of another cis-acting polymorphism affects ERBB4 expression in patients or that other SNPs or genes may compensate for the deficiency in the function of ERBB4. The lack of association of the ERBB4 gene in some studies is probably due to the dysfunction of other pathways and genes (e.g., NRG1, GLU, and GABA) that are involved in the compensation of gene expression. The NRG1-ERBB4 dysregulation might compensate for the changes in other pathways that use the ERBB4 receptor to mediate signaling (29) . For example, when NRG2 or NRG3 is downregulated, the NRG1-ERBB4 signaling pathway could be activated. Another reason is that the NRG1-ERBB4 pathway is a part of a large molecular complex that has many proteins linked to various signaling pathways. Banerjee et al. suggested that these pathways might communicate and coordinate with each other. As ERBB4 is a part of that complex, it may influence other pathways or be affected by those that have a role in Sz. ERBB4 and glutamatergic receptors are also anchored to the complex and concentrated in the postsynaptic density. ERBB4 can affect and change the glutamatergic receptor function and, in return, the glutamatergic receptors influence ERBB4 functions. Glutamatergic receptor hypofunction is found to be associated with Sz (29) .
Genotyping error in this study is unlikely to have occurred as a high-throughput sequencing technique was used, and resequencing of the samples was also performed in samples that had high noisy peaks or failed to display a result on the genetic analyzer. Another issue might arise regarding sex differences. However, this confounding factor was excluded in this study since all the patients included in the study were male. Finally, the genotyping process for the patients and controls was performed during the same period and under the same conditions.
In conclusion, this study is the first genetic analysis of the ERBB4 gene in Jordanian schizophrenic patients. No previous studies have been conducted on ERBB4 and its association with Sz in Arab nations. Herein, we relied on a sensitive sequencing technique for the genotyping process. The results proved that the intronic variant rs839523 was strongly associated with the risk of Sz in the Jordanian population (P = 0.006 for genotype and P = 0.002 for allele). In contrast, the exonic variant rs3748962 (Val1065Val) showed no significant association (P = 0.05 for genotype and P = 0.52 for allele) with this disorder in our Jordanian sample of Arab descent. Findings from this study support a genetic association of ERBB4 with Sz disorder. However, this study needs to be replicated in other ethnicities and specifically in Arabs in order to confirm these results. It is worth it to broaden this kind of research in the psychiatric field in order to improve the treatment and quality of health of patients.
